ArticleScience advances2020
Globally deimmunized lysostaphin evades human immune surveillance and enables highly efficacious repeat dosing.
Article in Science advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 29 citations in OpenAlex.
- Eradication of MRSA biofilm-associated implant infections by low-immunogenic sustained-release lysostaphin fused to thermosensitive polypeptides.Nature communications · 2026Article
- Novel endopeptidase overcoming lysostaphin resistance.Scientific reports · 2026Article
- A chimeric, half-life extended lysin with a unique mode of action.Frontiers in microbiology · 2026Article
- Multifunctional 3D-Printed Wound Dressings Containing a Combination of Synergistic Antimicrobials in the Management of MRSA Infected Topical Wounds.ACS applied materials & interfaces · 2025Article
- Enzyme-Based Anti-Inflammatory Therapeutics for Inflammatory Diseases.Pharmaceutics · 2025Review
- Agents Targeting the Bacterial Cell Wall as Tools to Combat Gram-Positive Pathogens.Molecules (Basel, Switzerland) · 2024Review
- Discovery of Antimicrobial Lysins from the "Dark Matter" of Uncharacterized Phages Using Artificial Intelligence.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Machine learning for functional protein design.Nature biotechnology · 2024Review
- Exploring the potential of naturally occurring antimicrobials for managing orthopedic-device-related infections.Journal of bone and joint infection · 2024Review
- Staphylococcus aureus sacculus mediates activities of M23 hydrolases.Nature communications · 2023Article
- Bioprospecting the Skin Microbiome: Advances in Therapeutics and Personal Care Products.Microorganisms · 2023Review
- Functional Deimmunization of Botulinum Neurotoxin Protease Domain via Computationally Driven Library Design and Ultrahigh-Throughput Screening.ACS synthetic biology · 2023Article
- Immunogenic epitope scanning in bacteriolytic enzymes Pal and Cpl-1 and engineering Pal to escape antibody responses.Frontiers in immunology · 2023Article
- A simple and efficient fluorescent labeling method inFrontiers in microbiology · 2023Article
- Impact of novel microbial secondary metabolites on the pharma industry.Applied microbiology and biotechnology · 2022Review
- One fold, many functions-M23 family of peptidoglycan hydrolases.Frontiers in microbiology · 2022Review
- The past, present, and future of enzyme-based therapies.Drug discovery today · 2022Review
- Bioinformatics-driven discovery of novel Clostridioides difficile lysins and experimental comparison with highly active benchmarks.Biotechnology and bioengineering · 2021Article
- MHCEpitopeEnergy, a Flexible Rosetta-Based Biotherapeutic Deimmunization Platform.Journal of chemical information and modeling · 2021Article
- Building blocks and blueprints for bacterial autolysins.PLoS computational biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
There is a critical need for novel therapies to treat methicillin-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.